Shelley Gandhi Joins Firm – Headlines ELIQUENT’s Expanded Pharmacovigilance Service Offerings
4.11.2024 21:50:00 EET | Business Wire | Press release
ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm, today announced that internationally recognized pharmacovigilance (PV) expert Shelley Gandhi has joined the firm. This strategic addition to ELIQUENT’s robust team of regulatory and quality leaders reinforces the firm’s commitment to delivering integrated solutions that streamline compliance, manage risk, and accelerate time-to-market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104361511/en/
Shelley Gandhi joins ELIQUENT Life Sciences - bolsters expanded Pharmacovigilance & Risk Management Solutions (Photo: Business Wire)
“Shelley’s firsthand knowledge of regulatory expectations and her proficiency in navigating complex regulatory challenges will be instrumental in expanding ELIQUENT’s pharmacovigilance solutions to meet the growing global demand for comprehensive safety and risk management across diverse markets,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences.
Global Pharmacovigilance Expertise
Shelley Gandhi brings more than three decades of global PV and risk management experience to her role at ELIQUENT. Her extensive professional background includes more than 19 years of service at the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). During her tenure, Shelley served in multiple senior positions where she gained extensive knowledge of all European regulatory processes relating to monitoring the safety of licensed medicinal products and ancillary devices.
Shelley’s distinguished MHRA career included a role as the UK representative on the European Medicines Agency’s (EMA) EudraVigilance Expert Working Group. In this capacity, Shelley was instrumental in shaping EMA’s system for managing and analyzing information on suspected adverse reactions to medicines. Her contributions further enhanced key PV processes and systems across Europe.
Prior to joining ELIQUENT, Shelley served for more than 12 years as a strategic PV advisor to clients building and managing risk management systems. Shelley provided support to biotechnology clients across a broad range of therapeutic areas. Her experience includes strategic and technical advisory services in multiple markets from early clinical development to launch readiness.
At ELIQUENT, Shelley works with clients to ensure compliance with global safety standards, while anticipating changes, and preparing proactive solutions. Her deep understanding of drug safety and risk management protocols, coupled with her regulatory and industry experiences, amplifies ELIQUENT’s expanded PV and Risk Management Solutions. Learn more about Shelley.
Pharmacovigilance & Post-Market Surveillance Solutions
ELIQUENT’s expanded PV and Risk Management Solutions optimize practices to ensure consistency, compliance and operational efficiency across diverse markets. With decades of experience developed as leaders in both the public and private sectors, ELIQUENT’s industry-recognized PV experts support innovators with precision and expertise - enabling clients to confidently navigate global post-marketing surveillance, adverse event reporting, and risk management planning. Because there is no one-size-fits-all approach, each solution is built to support regulatory objectives, while aligning with evolving global demands. ELIQUENT’s customized global Pharmacovigilance & Risk Management Solutions include:
- Global Support: Trusted guidance when navigating and complying with global PV regulations
- Adverse Event Reporting: Systematic identification, objective analysis, and strategic guidance responding to unintended occurrences
- Regulatory Reporting: Technical skill and institutional knowledge of complex regulatory reporting obligations
- Signal Detection: Expert development and implementation of detection processes, including reporting and risk communication
- Risk Assessment & Management: Proactive identification, assessment and planning to manage potential risk and ensure regulatory compliance
- Post-Marketing Surveillance: Established network experts to support commercial product safety systems and reporting function
- Risk Communications: Strategic development of communications plans to address emerging safety concerns and instill confidence in the market
- Clinical Trials Safety Oversight: On-demand resources to support safety monitoring before and after regulatory approval
- Qualified Person for Pharmacovigilance (QPPV): Comprehensive QPPV solutions ensure clients meet EU, UK, and regional pharmacovigilance requirements, while safeguarding patient safety.
- Global PV Training: Bespoke pharmacovigilance training programs to uphold the highest regulatory standards across diverse global markets.
Integrated Solutions – Full-Service Support
ELIQUENT redefines regulatory consulting with a full-service platform that delivers integrated solutions across the product lifecycle. The firm's unprecedented assembly of regulatory leaders, industry experts, and technical specialists collaborate seamlessly to advise clients on the complex process of bringing new therapies to market and manufacturing them to quality standards. ELIQUENT's integrated platform of regulatory solutions feature the following integrated service offerings:
- Regulatory Affairs Solutions: From the earliest phases of innovation through regulatory submissions, to post- approval support, ELIQUENT guides companies to approval and beyond.
- Pharmacovigilance & Risk Management Solutions: With an approach that includes both strategic direction and hands-on global support, customized PV solutions empower companies to operate with confidence.
- Quality & Compliance Solutions: Highly specialized compliance experts build customized solutions that equip companies with best- in-class strategic support, technical expertise, and project-based solutions.
- Remediations Solutions: Respected professionals and global experts bring an unmatched level of credibility and trust when interacting with regulators and guiding companies to remediation solutions.
- Talent Solutions: Whether you need a team of one or 100+, ELIQUENT’s talent solutions gives clients the ability to rapidly scale teams to the right size, with the right level of expertise, in the right locations.
About ELIQUENT Life Sciences
ELIQUENT Life Sciences is the fusion of six global regulatory consultancies: Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, RApport Global, and IDEC. ELIQUENT team works cross-functionally to deliver the global solutions that pharmaceutical, biotechnology, and medical device companies need to gain and maintain authorization for the products. ELIQUENT’s comprehensive services support innovators across therapeutic modalities, phase-based pathways, and major global markets. ELIQUENT’s continued growth is supported by GHO Capital, the European specialist investor in healthcare.
Learn more about ELIQUENT Life Sciences at eliquent.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104361511/en/
Contacts
Taryn Fritz Walpole
twalpole@eliquent.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi and Guru Partner to Deliver AI-Powered Enterprise Knowledge Enriched by Real-Time Data Activation14.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, and Guru, the AI-powered enterprise knowledge platform, today announced a technology partnership to help organizations unlock the full value of their enterprise data for AI-driven decision-making. Unveiled at Boomi World 2026, the partnership makes Guru a launch partner for Boomi Connect, Boomi’s new managed connector service, and integrates Guru’s knowledge agents with Agentstudio and the Boomi MCP Registry to deliver richer, more accurate, and more actionable insights to knowledge workers and AI agents alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514440755/en/ Guru was selected as a Boomi Connect launch partner because its AI-powered knowledge platform represents one of the highest-value consumption patterns for managed enterprise connectivity. Knowledge agents are only as effective as the data they can access, and Guru’s ability to synthesize insights across enterpris
IQM and Real Asset Acquisition Corp. Announce Public Filing of Form F-4 Registration Statement with the SEC14.5.2026 16:55:00 EEST | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced today the public filing of a registration statement on Form F-4 (the “Registration Statement”), which includes a preliminary proxy statement, with the U.S. Securities and Exchange Commission (“SEC”) in connection with the proposed Business Combination Agreement announced February 23, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514989293/en/ IQM Radiance quantum computer Jan Goetz, Chief Executive Officer and Co-Founder, IQM, said: “This filing is a milestone we have worked hard to reach, and it signals our readiness to operate at a new level. Public markets will give IQM the platform and capital to accelerate everything we are building as we work towards delivering fault-toleranc
MOBX to Acquire U.S. Defense Rare Earth, Critical Minerals Company14.5.2026 16:40:00 EEST | Press release
Mobix Labs (Nasdaq: MOBX) today announced a non-binding Letter of Intent to acquire Special Project Delivery LLC ("SPD"), a U.S. company building sovereign supply chains for rare earth elements, critical minerals, and energy storage. The proposed acquisition would extend Mobix Labs' national security work — already supplying U.S. and allied fighter jets, missiles, submarines, and satellites — directly into one of the world's most strategically important industrial sectors. MOBX is moving directly into the supply chain powering modern defense, aerospace, and AI infrastructure. Forward-Looking Statements This press release contains forward-looking statements regarding the proposed acquisition of Special Project Delivery LLC ("SPD"), which are subject to risks and uncertainties described in Mobix Labs' SEC filings and similar provisions under applicable non-U.S. securities laws. The Letter of Intent is non-binding, and there can be no assurance that a definitive agreement will be executed
Flick Raises $6M Seed Round to Redefine How AI Films Are Created14.5.2026 16:19:00 EEST | Press release
Flick (flick.art), an AI-native filmmaking platform founded by award-winning filmmaker Zoey Zhang and founding Instagram engineer Ray Wang, today announced it has raised $6 million in a seed round from True Ventures, GV (Google Ventures), Y Combinator, Lightspeed, Formosa Capital, Pioneer Fund, Olive Tree Capital, and N1 in addition to angel investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514408256/en/ Flick was built around a simple belief: AI should enhance filmmaking, not replace it. Instead of another one-click video generator, Flick gives filmmakers cinematic control through an AI-native creative workflow designed for storytelling, iteration, and artistic direction. Flick will use the seed funding to accelerate product development, expand its core creative tooling for cinematic control, and grow the company’s community of filmmakers. The team is also launching Flick Filmmaker Residency,debuting with 10+ sho
PIF Named as Official Tournament Supporter of FIFA World Cup 2026™14.5.2026 16:08:00 EEST | Press release
PIF and FIFA has announced PIF as an Official Tournament Supporter in North America and Asia of the FIFA World Cup 2026™. The partnership reflects a shared commitment to expanding the growth of football at every level, from the grassroots to elite competition, as well as enabling greater participation in sport by unlocking new opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514974404/en/ 14 May, 2026: Front row (L-R), Romy Gai, Chief Business Officer, FIFA and Kevin Foster, Managing Director and Head of Corporate Affairs, PIF, back row (L-R), H.R.H Prince Faisal Bin Bandar Bin Sultan Al Saud, Vice Chairman, Savvy Games Group, Gianni Infantino, President, FIFA, H.E. Yasir Othman Al-Rumayyan, Governor, PIF and Muhannad AlDawood, Chief Strategy Officer, Qiddiya Investment Company witnessed the signing of the partnership of PIF as Official Tournament Supporter of FIFA World Cup 2026™, incorporating PIF companies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom